Inventor

KRUIDENIER LAURENS

US4 patents

⚠️ This page may combine multiple inventors who share the name “KRUIDENIER LAURENS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

PROMETHEUS BIOSCIENCES INC

3 patents

US11136386B2Oct 5, 2021

Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)

PROMETHEUS BIOSCIENCES INC12 citations82

US12215147B2Feb 4, 2025

Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody

PROMETHEUS BIOSCIENCES INC1 citations71

US12391752B2Aug 19, 2025

Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease

PROMETHEUS BIOSCIENCES INC0 citations59

KRUIDENIER LAURENS

1 patent

US8691747B2Apr 8, 2014

Method of treatment based on ATAD2 inhibitors

KRUIDENIER LAURENS21 citations86

KRUIDENIER LAURENS

PROMETHEUS BIOSCIENCES INC

Methods of treating Crohn&#39;s disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)

Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody

Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease

KRUIDENIER LAURENS

Method of treatment based on ATAD2 inhibitors

Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)